tiprankstipranks
Trending News
More News >
Therapeutic Solutions International (TSOI)
:TSOI
US Market
Advertisement

Therapeutic Solutions International (TSOI) Price & Analysis

Compare
66 Followers

TSOI Stock Chart & Stats

<$0.01
>-$0.01(-16.67%)
At close: 4:00 PM EST
<$0.01
>-$0.01(-16.67%)

TSOI FAQ

What was Therapeutic Solutions International’s price range in the past 12 months?
Currently, no data Available
What is Therapeutic Solutions International’s market cap?
Therapeutic Solutions International’s market cap is $512.27K.
    When is Therapeutic Solutions International’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Therapeutic Solutions International’s earnings last quarter?
    Currently, no data Available
    Is Therapeutic Solutions International overvalued?
    According to Wall Street analysts Therapeutic Solutions International’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
      Does Therapeutic Solutions International pay dividends?
      Therapeutic Solutions International does not currently pay dividends.
      What is Therapeutic Solutions International’s EPS estimate?
      Therapeutic Solutions International’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Therapeutic Solutions International have?
      Therapeutic Solutions International has 5,122,705,600 shares outstanding.
        What happened to Therapeutic Solutions International’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Therapeutic Solutions International?
        Currently, no hedge funds are holding shares in TSOI

        Company Description

        Therapeutic Solutions International

        Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, traumatic brain injury, and lung pathologies, as well as for daily health. Its flagship products include QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production. The company also produces nutraceuticals, including ProJuvenol, a synergistic blend of complex anti-aging ingredients in capsules; NanoStilbene, a nanoemulsion of nanoparticle pterostilbene; DermalStilbene, a topical form of pterostilbene delivered through spray application onto skin; IsoStilbene, an injectable formulation of pterostilbene; NeuroStilbene, an intranasal form of pterostilbene; NanoPlus, a blend of NanoStilbene and Nano Cannabidiol; Nano Cannabidiol, a nanoparticle formulation of cannabidiol; NanoPSA, a blend of NanoStilbene and broccoli sprout extract; and NLRP3 Trifecta, a two-product combo that consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract. It is also developing therapeutics in chronic traumatic encephalopathy, and traumatic brain injury and lung pathology. Therapeutic Solutions International, Inc. was founded in 2007 and is based in Elk City, Idaho.
        Similar Stocks
        Company
        Price & Change
        Follow
        TNF Pharmaceuticals
        Entero Therapeutics
        Protagenic Therapeutics
        ZyVersa Therapeutics
        PMGC Holdings

        Ownership Overview

        15.04%<0.01%100.00%
        15.04% Insiders
        <0.01% Other Institutional Investors
        100.00% Public Companies and
        Individual Investors

        Options Prices

        Currently, No data available
        ---
        Popular Stocks
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis